On July 8, 2025, Salarius Pharmaceuticals, Inc. announced that its stockholders approved a reverse stock split between 1:4 and 1:40 and a share issuance to comply with Nasdaq rules. About 37% of stockholders participated in the vote, with 561,364 votes in favor of the reverse split and 124,631 votes for the issuance proposal.